This is a positive clinical proof-of-concept for Alpha DaRT in glioblastoma outside the U.S., but it is a single-patient case under a broad-access protocol, not a controlled trial. Traders should watch for enrollment updates and data from the U.S. REGAIN trial, as well as any subsequent regulatory or partnership developments that could de-risk the program.
Price Chart
Executive Summary
Alpha Tau announced the first-ever treatment of a recurrent glioblastoma patient outside the U.S. using its Alpha DaRT technology at Hadassah University Medical Center in Israel. The procedure was completed safely without unexpected complications, marking the first international clinical application of the brain-specific delivery system and adding momentum to the ongoing U.S. REGAIN trial.
Key Facts
- First recurrent glioblastoma patient treated with Alpha DaRT outside the U.S., and first in Israel, at Hadassah University Medical Center.
- Procedure used proprietary brain applicator with real-time stereotactic neuro-navigation via a single minimally-invasive burr hole.
- Patient was a 77-year-old male with recurrent glioblastoma following surgery and radiation therapy; procedure completed safely without unexpected complications.
- Treatment was under the ALL clinical protocol, a broad-access study at Hadassah open to patients with solid tumors amenable to Alpha DaRT.
- The company references its multicenter U.S. Recurrent GBM REGAIN trial, which is continuing recruitment following interim results and FDA clearance to proceed to full enrollment with two new U.S. academic centers.
Financial Impact
No financial figures provided; clinical milestone with no revenue or cost data disclosed.
Risk Factors
- Single-patient case under a broad-access protocol; no controlled efficacy data provided.
- Glioblastoma is a highly aggressive disease; safety and efficacy in larger populations remain unproven.
- Company is pre-revenue and will require additional capital to fund ongoing trials and operations.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-071076 |
| Document: ea029546701ex99-1.htm | 0001213900-26-071076 |
| Document: 0001213900-26-071076-index-headers.html | 0001213900-26-071076 |
| Document: 0001213900-26-071076-index.html | 0001213900-26-071076 |
| Document: 0001213900-26-071076.txt | 0001213900-26-071076 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | 6-K | $14.11 $15.19 | ▲ +7.65% | ▲ +7.84% | $14.77 (+4.68%) |
Aug 10, 2026 7w ago | 6-K | $14.27 $14.27 | · 0.00% | ▲ +1.06% | $14.77 (+3.50%) |
Aug 10, 2026 7w ago | Press Release | $14.27 $14.27 | · 0.00% | ▲ +1.06% | $14.77 (+3.50%) |
Aug 10, 2026 7w ago | 6-K | $13.60 $14.84 | ▲ +9.12% | ▲ +10.03% | $14.77 (+8.60%) |
Jul 21, 2026 10w ago | 6-K | $13.32 $14.26 | ▲ +7.06% | ▲ +4.50% | $14.77 (+10.89%) |
Jul 15, 2026 11w ago | 6-K | $12.46 $13.87 | ▲ +11.32% | ▲ +8.97% | $14.77 (+18.54%) |
Jun 23, 2026 14w ago | 6-K | $10.05 $13.01 | ▲ +29.45% | ▲ +27.52% | $14.77 (+46.97%) |
Jun 3, 2026 17w ago | Press Release | $10.58 $13.23 | ▲ +25.05% | ▲ +26.05% | $14.77 (+39.60%) |
May 11, 2026 20w ago | Press Release | $10.34 $9.19 | ▼ −11.12% | ▼ −10.82% | $14.77 (+42.84%) |
May 8, 2026 21w ago | Press Release | $8.51 $9.35 | ▲ +9.87% | ▲ +9.85% | $14.77 (+73.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access